Shenzhen YHLO Biotech (SH:688575) Xin Lang Cai Jing·2026-02-09 10:42Core Viewpoint - The company, specializing in the IVD (in vitro diagnostics) sector, is under investigation by the China Securities Regulatory Commission (CSRC) for alleged misleading disclosures related to a strategic cooperation agreement with Shenzhen Brain Machine Star Chain Technology Co., Ltd. [2][7] Company Overview - The company is engaged in the research, production, sales, and service of IVD products and is recognized as a national high-tech enterprise with numerous intellectual property rights [6][7] - It has received multiple awards, including the Shenzhen Science and Technology Progress Award and the Guangdong Province Patent Award [6] Regulatory Issues - On February 6, 2026, the CSRC issued a notice of investigation due to potential violations of information disclosure laws concerning the strategic cooperation agreement with Brain Machine Star Chain [2][7] - The initial announcement on January 6, 2026, claimed collaboration in product development and market promotion, but subsequent disclosures clarified that the products were still in early research or preclinical stages [2][7] Market Reaction - The "brain-machine interface" concept is currently a market hotspot, leading to a significant increase in the company's stock price, which rose by 6.52% with trading volume up by 299% compared to the previous day [3][8] - The company is urged to ensure that all disclosures related to this hot topic are accurate and complete to avoid misleading investors [3][8]